2024-10-18 23:40:00
By Patricia Vilas Boas
SAO PAULO (Reuters) – Hypera (BVMF:) said on Friday that it had decided to reduce the policy of payment terms granted to customers, to optimize working capital, in addition to interrupting its projections for the year, according to a fact relevant to the market.
The company said this reduction aims to “potentially” increase operating cash generation by 2.5 billion reais by 2028 and 7.5 billion reais over the next ten years.
According to the pharmaceutical group, the decision does not change the focus on its growth strategy in direct sales to consumers, the so-called “sell out” – which grew by around 13% in October and by around 11% in the third quarter – as well as in portfolio diversification.
The company also released some preliminary results for the third quarter, ahead of a full earnings release on November 13.
The preview of the results, unaudited and still subject to audit, indicates the company’s net revenue of approximately 1.9 billion reais in the quarter ended in September, as well as an Ebitda close to 561 million reais and a net profit of approximately 370 million reais.
Projections for 2024, which were discontinued, included net sales of nearly 8.6 billion reais, adjusted EBITDA from continuing operations of approximately 3 billion reais, and net income from continuing operations near 1.85 billion reais. reais.
Hypera, which has pharmaceutical brands such as Buscopan, Coristina and Neosaldina in its portfolio, also announced in the same press release that its board of directors has approved a buyback program of up to 30 million shares, with a duration of 18 months and starting from this Friday.
#Hypera #reduces #payment #terms #policy #halts #projections #Reuters